61 Results
Statement—Investigational AstraZeneca Vaccine Prevents COVID-19
March 22, 2021
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization.
Statement—NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies
March 4, 2021
The NIH ACTIV-3 clinical trial, which evaluates investigational therapeutics for COVID-19 in hospitalized patients, closed enrollment in two sub-studies.
Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Janssen COVID-19 Vaccine
February 27, 2021
Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the Janssen Pharmaceuticals Companies of Johnson & Johnson for its single-shot COVID-19 vaccine, called Ad.26.COV2S or JNJ-78436725. The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the spike protein found on the surface of the SARS-CoV-2 virus that causes COVID-19.
Monoclonal Antibodies Against MERS Coronavirus Show Promise in Phase 1 NIH-Sponsored Trial
February 23, 2021
A NIH-sponsored Phase 1 clinical trial of two mAbs directed against the coronavirus that causes MERS found they were well tolerated and generally safe.
Statement—Four Potential COVID-19 Therapeutics Enter Phase 2/3 Testing in NIH ACTIV-2 Trial
February 12, 2021
Enrollment has begun to test additional investigational drugs in the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program.
NIH Experts Discuss SARS-CoV-2 Viral Variants
February 12, 2021
The rise of several significant variants of SARS-CoV-2 has attracted the attention of health and science experts worldwide, NIH reports.
Clinical Trial in Hospitalized COVID-19 Patients Evaluates Long-Acting Antibody Therapy
February 8, 2021
A NIAID clinical trial began evaluating the safety of an investigational long-acting antibody combination for people hospitalized with COVID-19.
Statement—Janssen Investigational COVID-19 Vaccine—Interim Analysis
January 29, 2021
NIH reports that an investigational COVID-19 vaccine by Janssen Pharmaceuticals appears to be safe and effective at preventing COVID-19 in adults.
Bulletin—Update on SARS-CoV-2 Variants
January 27, 2021
Recently, NIH notes that media reports and pre-print scientific papers on SARS-CoV-2 variants have discussed various genetic mutations in the virus.
Media Availability—NIH Officials Highlight COVID-19 Vaccine Facts, Unknowns for Healthcare Providers
January 18, 2021
NIAID Director urges healthcare providers to be able to explain the latest data supporting the safety and efficacy of vaccines for COVID-19.
Statement—Large Clinical Trial Will Test Combination Monoclonal Antibody Therapy for Mild/Moderate COVID-19
January 5, 2021
A NIAID-supported clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy for people with mild to moderate COVID-19.
